ArticleJMIR cancer2024

Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes.

Andreas Trojan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.